BIIB•benzinga•
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
Summary
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga